Literature DB >> 11470562

5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells.

W Li1, W J Zhang, K Ohnishi, I Yamada, R Ohno, K Hashimoto.   

Abstract

To verify if photodynamic therapy (PDT) could overcome multidrug resistance (MDR) when it it applied to eradicate minimal residual disease in patients with leukemia, we investigated the fluorescence kinetics of 5-aminolaevulinic acid (ALA)-induced protoporphyrin IX (PpIX) and the effect of subsequent photodynamic therapy on MDR leukemia cells, which express P-glycoprotein (P-gp), as well as on their parent cells. Evaluation of PpIX accumulation by flow cytometry showed that PpIX accumulated at higher levels in mdr-1 gene-transduced MDR cells (NB4/MDR) and at lower levels in doxorubicin-induced MDR cells (NOMO-1/ADR) than in their parent cells. A P-gp inhibitor could not increase PpIX accumulation. Measurement of extracellular PpIX concentration by fluorescence spectrometry showed that P-gp did not mediate the fluorescence kinetics of ALA-induced PpIX production. Assessment of ferrochelatase activity using high-performance liquid chromatography indicated that PpIX accumulation in drug-induced MDR cells was probably regulated by this enzyme. Assessment of phototoxicity of PDT using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that PDT was effective in NB4, NB4/MDR, NOMO-1 and NOMO-1/ADR cells, which accumulated high levels of PpIX, but not effective in K562 and K562/ADR cell lines, which accumulated relatively low levels of PpIX. These findings demonstrate that P-gp does not mediate the ALA-fluorescence kinetics, and multidrug resistant leukemia cells do not have cross-resistance to ALA-PDT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470562     DOI: 10.1016/s1011-1344(01)00124-5

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  8 in total

Review 1.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Substrate affinity of photosensitizers derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population stem cell-like cancer cells to photodynamic therapy.

Authors:  Janet Morgan; Jennifer D Jackson; Xiang Zheng; Suresh K Pandey; Ravindra K Pandey
Journal:  Mol Pharm       Date:  2010-09-01       Impact factor: 4.939

3.  Therapeutic effects of systemic photodynamic therapy in a leukemia animal model using A20 cells.

Authors:  Lan Ying Wen; Su-Mi Bae; Heung-Jae Chun; Kye-Shin Park; Woong Shick Ahn
Journal:  Lasers Med Sci       Date:  2011-07-18       Impact factor: 3.161

4.  Bypass of tumor drug resistance by antivascular therapy.

Authors:  Dina Preise; Ohad Mazor; Natalia Koudinova; Mordechai Liscovitch; Avigdor Scherz; Yoram Salomon
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

5.  Bioluminescence-activated deep-tissue photodynamic therapy of cancer.

Authors:  Yi Rang Kim; Seonghoon Kim; Jin Woo Choi; Sung Yong Choi; Sang-Hee Lee; Homin Kim; Sei Kwang Hahn; Gou Young Koh; Seok Hyun Yun
Journal:  Theranostics       Date:  2015-04-18       Impact factor: 11.556

6.  The effects of photodynamic therapy on leukemia cells mediated by KillerRed, a genetically encoded fluorescent protein photosensitizer.

Authors:  Meng Yuan; Chengcheng Liu; Jiao Li; Wenpeng Ma; Xiaozhuo Yu; Ping Zhang; Yanhong Ji
Journal:  BMC Cancer       Date:  2019-10-07       Impact factor: 4.430

7.  Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a.

Authors:  Patrick Ming-Kuen Tang; Dong-Mei Zhang; Ngoc-Ha Bui Xuan; Stephen Kwok-Wing Tsui; Mary Miu-Yee Waye; Siu-Kai Kong; Wing-Ping Fong; Kwok-Pui Fung
Journal:  Mol Cancer       Date:  2009-07-31       Impact factor: 27.401

8.  5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy.

Authors:  Yasuhisa Sando; Ken-Ichi Matsuoka; Yuichi Sumii; Takumi Kondo; Shuntaro Ikegawa; Hiroyuki Sugiura; Makoto Nakamura; Miki Iwamoto; Yusuke Meguri; Noboru Asada; Daisuke Ennishi; Hisakazu Nishimori; Keiko Fujii; Nobuharu Fujii; Atae Utsunomiya; Takashi Oka; Yoshinobu Maeda
Journal:  Sci Rep       Date:  2020-10-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.